Enzo Sanzaro
Research Subjects
Research Interests
Enzo Sanzaro has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Carmela Zizzo
Institute of Biomedicine and Molecular Immunology "A. Monroy", National Research Council, Palermo, Italy
1 shared publication - Caterina Bono
National Research Council-Institute of Biomedicine and Molecular Immunology (CNR-IBIM) - Palermo, Italy
1 shared publication - Daniele Francofonte
National Research Council-Institute of Biomedicine and Molecular Immunology (CNR-IBIM) - Palermo, Italy
1 shared publication - Domenico Nuzzo
Institute for Biomedical Research and Innovation, National Research Council of Italy, Palermo, Italy
1 shared publication - Francesco Iemolo
CNR-IBIM: Institute of Biomedicine and Molecular Immunology “A. Monroy”, Via Ugo la Malfa n.153, Palermo, Italy
1 shared publication - Giovanni Duro
Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy
1 shared publication
Latest Publications
- Open Access
- 6 September 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 323
Genetic screening of Fabry patients with EcoTILLING and HRM technology
Anderson-Fabry disease (FD) is caused by a deficit of the α-galactosidase A enzyme which leads to the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body, causing the onset of a multi-systemic disease with poor prognosis in adulthood. In this article, we describe two alternative methods for screening the GLA gene which codes for the α-galactosidase A enzyme in subjects with probable FD in order to test analysis strategies which include or rely on initial pre-screening.
- 6 September 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 323
Open AccessGenetic screening of Fabry patients with EcoTILLING and HRM technology
Anderson-Fabry disease (FD) is caused by a deficit of the α-galactosidase A enzyme which leads to the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body, causing the onset of a multi-systemic disease with poor prognosis in adulthood. In this article, we describe two alternative methods for screening the GLA gene which codes for the α-galactosidase A enzyme in subjects with probable FD in order to test analysis strategies which include or rely on initial pre-screening.